MESO
Mesoblast Limited
NASDAQ · AUHealthcareBiotechnology
$16.63-3.98%
Price as of Jul 20, 2026
MESO financials
Mesoblast Limited financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $17.2M | $5.9M | $7.5M | $10.2M |
| Cost of revenue | $5.1M | $41.1M | $54.9M | $63.6M |
| Gross profit | $12.1M | -$35.2M | -$47.4M | -$53.4M |
| Operating expenses | $74.5M | $49.0M | $76.8M | $90.8M |
| Operating income | -$62.4M | -$84.1M | -$69.3M | -$80.6M |
| Net income | -$102.1M | -$88.0M | -$81.9M | -$91.3M |
| EBITDA | -$73.7M | -$56.1M | -$58.5M | -$76.6M |
| Basic EPS | $-0.84 | $-0.89 | $-0.98 | $-1.30 |
| Diluted EPS | $-0.84 | $-0.89 | $-0.98 | $-1.30 |
| Balance sheet | ||||
| Cash & equivalents | $161.2M | $62.6M | $70.9M | $60.0M |
| Total assets | $784.7M | $669.2M | $669.4M | $662.1M |
| Total liabilities | $187.2M | $188.8M | $167.6M | $165.1M |
| Stockholders’ equity | $597.4M | $480.4M | $501.8M | $497.0M |
| Total debt | $128.2M | $118.9M | $116.5M | $106.9M |
| Net debt | -$33.0M | $56.4M | $45.6M | $46.9M |
| Cash flow | ||||
| Operating cash flow | -$50.0M | -$48.5M | -$63.3M | -$65.8M |
| Capital expenditure | -$730.0K | -$331.0K | -$314.0K | -$232.0K |
| Free cash flow | -$50.7M | -$48.8M | -$63.6M | -$66.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |